Cg Oncology, Inc. (CGON) SEC Filings — 2025
13 SEC filings for Cg Oncology, Inc. (CGON) in 2025.
Filings
- CG Oncology Relocates HQ, Hints at Officer/Director Changes — 8-K · Nov 26, 2025
- CG Oncology's Losses Mount Amid R&D Surge, Cash Dips to $45M — 10-Q · Nov 14, 2025
- CG Oncology Files 8-K — 8-K · Sep 9, 2025
- CG Oncology Files 8-K Report — 8-K · Sep 5, 2025
- CG Oncology's Losses Widen Amid Surging R&D for Bladder Cancer Drug — 10-Q · Aug 8, 2025
- CG Oncology Announces Board and Compensation Changes — 8-K · Jul 11, 2025
- CG Oncology Reports on Shareholder Vote Matters — 8-K · Jun 6, 2025
- CG Oncology Q1 2025 Update: R&D Expenses and Stock Plan Details — 10-Q · May 13, 2025
- CG Oncology & Bristol Myers Squibb Trial Bladder Cancer Combo — 8-K · Apr 28, 2025
- CG Oncology Files Definitive Proxy Statement — DEF 14A · Apr 25, 2025
- Cg Oncology, Inc. 10-K Filing — 10-K · Mar 28, 2025
- CG Oncology Files 8-K Report — 8-K · Mar 24, 2025
- CG Oncology Appoints New Chief Medical Officer — 8-K · Jan 10, 2025